Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
// Sheng-Fan Wang 1, 2 , Meng-Shian Chen 1 , Yueh-Ching Chou 1, 2, 3 , Yune-Fang Ueng 1, 4, 5 , Pen-Hui Yin 6 , Tien-Shun Yeh 7 , Hsin-Chen Lee 1 1 Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei, Taiwan 2 Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan 3 School of Pharmacy, Taipei Medical University, Taipei, Taiwan 4 National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan 5 Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan 6 Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan 7 Institute of Anatomy and Cell Biology, School of Medicine, National Yang-Ming University, Taipei, Taiwan Correspondence to: Hsin-Chen Lee, email: hclee2@ym.edu.tw Keywords: gastric cancer, mitochondrial dysfunction, cisplatin resistance, xCT, retrograde signaling Received: June 14, 2016 Accepted: September 21, 2016 Published: September 30, 2016 ABSTRACT Mitochondrial DNA mutations and defects in mitochondrial enzymes have been identified in gastric cancers, and they might contribute to cancer progression. In previous studies, mitochondrial dysfunction was induced by oligomycin-enhanced chemoresistance to cisplatin. Herein, we dissected the regulatory mechanism for mitochondrial dysfunction-enhanced cisplatin resistance in human gastric cancer cells. Repeated cisplatin treatment-induced cisplatin-resistant cells exhibited high SLC7A11 (xCT) expression, and xCT inhibitors (sulfasalazine or erastin), xCT siRNA, or a GSH synthesis inhibitor (buthionine sulphoximine, BSO) could sensitize these cells to cisplatin. Clinically, the high expression of xCT was associated with a poorer prognosis for gastric cancer patients under adjuvant chemotherapy. Moreover, we found that mitochondrial dysfunction enhanced cisplatin resistance and up-regulated xCT expression, as well as intracellular glutathione (GSH). The xCT inhibitors, siRNA against xCT or BSO decreased mitochondrial dysfunction-enhanced cisplatin resistance. We further demonstrated that the upregulation of the eIF2α-ATF4 pathway contributed to mitochondrial dysfunction-induced xCT expression, and activated eIF2α kinase GCN2, but not PERK, stimulated the eIF2α-ATF4-xCT pathway in response to mitochondrial dysfunction-increased reactive oxygen species (ROS) levels. In conclusion, our results suggested that the ROS-activated GCN2-eIF2α-ATF4-xCT pathway might contribute to mitochondrial dysfunction-enhanced cisplatin resistance and could be a potential target for gastric cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335 · cited 3×
“glutathione (GSH), increased DNA damage repair, and the inhibition of apoptosis [11].”
BackgroundIshimoto, T., Nagano, O., Yae, T., Tamada, M., Motohara, T., Oshima, H., Oshima, M., Ikeda, T., Asaba, R., Yagi, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.038 · Cited by 1,192 · cited 3×
“xCT not only has been proposed as a possible target for cisplatin resistance but also for comprehensive chemoresistance or targeted therapy resistance [39, 44, 45].”
BackgroundWagner, A. D., Grothe, W., Haerting, J., Kleber, G., Grothey, A., & Fleig, W. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.0245 · Cited by 1,171 · cited 1×
“Systemic chemotherapy based on 5-fluorouracil (5-FU) plus an anthracycline agent or cisplatin-containing combinations, is the most effective treatment modality for patients with metastatic disease [2].”
BackgroundHarris, I. S., Treloar, A. E., Inoue, S., Sasaki, M., Gorrini, C., Lee, K. C., Yung, K. Y., Brenner, D., Knobbe-Thomsen, C. B., Cox, M. A., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.019 · Cited by 993
Mitonuclear communication in homeostasis and stress
Quirós, P. M., Mottis, A., & Auwerx, J. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.23 · Cited by 787 · cited 3×
“Mitochondrial dysfunction has been suggested to contribute to cancer progression [7, 8].”
BackgroundTimmerman, L. A., Holton, T., Yuneva, M., Louie, R. J., Padró, M., Daemen, A., Hu, M., Chan, D. A., Ethier, S. P., van ‘t Veer, L. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.020 · Cited by 573 · cited 1×
“Increased xCT expression has been found to be essential for cancer proliferation and malignant progression in certain cancer cells [36, 37].”
BackgroundThe x cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases
Lo, M., Wang, Y., & Gout, P. W. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21366 · Cited by 399 · cited 4×
“This transporter is known to contribute to the maintenance of intracellular GSH levels and to protect cells from oxidative stress or toxic compounds [13].”
BackgroundInfluential
Cited by
ROS and the DNA damage response in cancer
Srinivas, U. S., Tan, B. W. Q., Vellayappan, B. A., & Jeyasekharan, A. D. (2019) · Redox Biology · doi:10.1016/j.redox.2018.101084 · Cited by 2,144
Modulating ROS to overcome multidrug resistance in cancer
Cui, Q., Wang, J.-Q., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Yang, D.-H., & Chen, Z.-S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.001 · Cited by 661
Regulation of Nrf2 by Mitochondrial Reactive Oxygen Species in Physiology and Pathology
Kasai, S., Shimizu, S., Tatara, Y., Mimura, J., & Itoh, K. (2020) · Biomolecules · doi:10.3390/biom10020320 · Cited by 566
The Role of Erastin in Ferroptosis and Its Prospects in Cancer Therapy
Zhao, Y., Li, Y., Zhang, R., Wang, F., Wang, T., & Jiao, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s254995 · Cited by 458
Ferroptosis Mechanisms Involved in Neurodegenerative Diseases
Reichert, C. O., de Freitas, F. A., Sampaio-Silva, J., Rokita-Rosa, L., Barros, P. D. L., Levy, D., & Bydlowski, S. P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228765 · Cited by 422
Metadata
- Authors
- Wang, S.-F., Chen, M.-S., Chou, Y.-C., Ueng, Y.-F., Yin, P.-H., Yeh, T.-S., & Lee, H.-C.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-09-30
- Volume
- 7
- Issue
- 45
- Pages
- 74132-74151
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2525112160
- Cited by
- 93
- References
- 7
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway. https://app.cochat.ai/papers/10.18632/oncotarget.12356
- The paper
- Wang, S.-F., Chen, M.-S., Chou, Y.-C., Ueng, Y.-F., Yin, P.-H., Yeh, T.-S., & Lee, H.-C. (2016). Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway. Oncotarget. https://doi.org/10.18632/oncotarget.12356
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.